Sol-Gel Technologies Ltd.: Opaleye Management Inc. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Opaleye Management Inc. amended its Schedule 13G filing for Sol-Gel Technologies Ltd., updating its disclosed stake in the dermatology-focused company under SEC accession 0001493152-26-050454. The filing reflects a change in the investment manager's reported position, though the amended disclosure did not specify a revised percentage in the headline. Schedule 13G amendments are typically filed by passive investors when their ownership crosses or adjusts around the 5% threshold, making the update a signal of shifting institutional interest in the small-cap biotech. Investors will watch for the full filing details to confirm whether Opaleye increased or trimmed its holding and whether the change reflects broader repositioning in Sol-Gel's shares.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Sol-Gel Technologies Ltd., Opaleye Management Inc.